(24/7 MARKET NEWS) — Titan Pharmaceuticals Inc. (NASDAQ: TTNP) has been steadily climbing today, after announcing that the FDA cleared its Investigational New Drug application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder.
It’s trading at $0.7515, up 0.1465 (+24.22%), on 1,267,766 shares traded, with most of the price movement just beginning.
[mstock id=”73007″ asset=”ttnp”]
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.